5 recruiting, 4 completed, 2 not yet recruiting. 6 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Not yet recruiting 2, Recruiting 2 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow Kind Pharmaceuticals LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy AND017 - Chemotherapy Induced Anemia | Phase 2 | Not yet recruiting | Kind Pharmaceuticals LLC | 36 | 2027-12-01 | 2026-09-01 |
| A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy AND017 - Cancer-Related Anemia | Phase 2 | Not yet recruiting | Kind Pharmaceuticals LLC | 36 | 2027-12-01 | 2026-09-01 |
| A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) AND017, ESA - Anemia Due to Chronic Kidney Disease | Phase 3 | Recruiting | Kind Pharmaceuticals LLC | 240 | 2025-12-03 | 2026-03-27 |
| A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia AND017 capsules, ESA - Anemia Due to Chronic Kidney Disease | Phase 3 | Recruiting | Kind Pharmaceuticals LLC | 300 | 2025-10-31 | 2026-03-27 |
| A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome AND017 - Myelodysplastic Syndromes | Phase 2 | Recruiting | Kind Pharmaceuticals LLC | 63 | 2025-03-14 | 2026-02-27 |
| A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia AND017 capsules, AND017 Placebo - β -Thalassemia | Phase 2 | Recruiting | Kind Pharmaceuticals LLC | 64 | 2024-05-27 | 2026-02-27 |
| A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars - Renal Anemia | Phase 2 | Completed | Kind Pharmaceuticals LLC | 175 | 2023-05-03 | 2024-06-28 |
| A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer AND019 PO QD - Advanced or Metastatic Breast Cancer | Phase 1 | Recruiting | Kind Pharmaceuticals LLC | 61 | 2022-10-05 | 2026-02-27 |
| A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients AND017, Placebo - Renal Anemia | Phase 2 | Completed | Kind Pharmaceuticals LLC | 113 | 2021-10-18 | 2023-10-04 |
| A Food-Effect Study of AND017 in Healthy Participants AND017 - Healthy Volunteers | Phase 1 | Completed | Kind Pharmaceuticals LLC | 14 | 2020-07-30 | 2021-05-11 |
| A Dose-escalation Study of AND017 in Healthy Subjects AND017 single dose, AND017 multiple dose, Placebo - Healthy Volunteers | Phase 1 | Completed | Kind Pharmaceuticals LLC | 78 | 2018-07-16 | 2021-05-11 |
Anemia (2) · Breast Neoplasms (1) · Myelodysplastic Syndromes (1)
Darbepoetin alfa (1) · Epoetin Alfa (1) · continuous erythropoietin receptor activator (1)
China (7) · United States (3) · Australia (1)
Yusha Zhu, MD, PhD (6) · Yusha Zhu, MD PhD (4)